

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

JACKSON *et al.*

Appl. No.: 10/766,711

Filed: January 27, 2004

For: **Chlamydia Protein, Gene
Sequence and Uses Thereof**

Confirmation No.: 4900

Art Unit: 1645

Examiner: BASKAR, Padmavathi

Atty. Docket: 2479.0040003/EJH/C-K

**Second Supplemental Information Disclosure Statement
Under 37 C.F.R. § 1.97(c)**

Mail Stop Amendment
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on accompanying IDS Forms, PTO/SB/08A and PTO/SB/08B, are documents that may be considered material to the patentability of this application as defined in 37 C.F.R. §1.56, and in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.97 and 1.98. The numbering on this Second Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' First Supplemental Information Disclosure Statement filed on November 17, 2006, in connection with the above-captioned application.

Copies of documents, **FP2** and **NPL33**, are submitted.

The Examiner's attention is directed to the following PCT publication, which is directed to related technical subject matter.

International Publication No. WO 99/17741 (Document **FP2**), inventors Jackson, W. J., *et al.*, filed October 1, 1998, listed as **FP2**.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection, or Notice of Allowance, or an action that otherwise closes prosecution in the application. Attached is our PTO-2038 Credit Card Payment Form in the amount of \$180.00 in payment of the fee under 37 C.F.R. § 1.17(p).

It is respectfully requested that the Examiner initial and return a copy of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

A handwritten signature in black ink, appearing to read "Elizabeth J. Haanes", is written over the printed name and title.

Elizabeth J. Haanes, Ph.D.
Attorney for Applicants
Registration No. 42,613

Date: May 23, 2008

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600
824564_1